IMPACT OF BASELINE MODIFIED RHEUMATIC DISEASE COMORBIDITY INDEX (MRDCI) ON DRUG SURVIVAL AND EFFECTIVENESS OF BIOLOGICAL DRUGS IN PATIENTS AFFECTED WITH RHEUMATOID ARTHRITIS (RA), SPONDYLOARTHRITIS (SPA), AND PSORIATIC ARTHRITIS (PSA) IN REAL-WORLD SETTINGS / Fornaro, M; Di Carlo, M; Gentileschi, S; Giannotta, Mg; Cantarini, L; Salaffi, F; Lapadula, G; Lannone, F. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - STAMPA. - 76:(2017), pp. 259-259. [10.1136/annrheumdis-2017-eular.1502]
IMPACT OF BASELINE MODIFIED RHEUMATIC DISEASE COMORBIDITY INDEX (MRDCI) ON DRUG SURVIVAL AND EFFECTIVENESS OF BIOLOGICAL DRUGS IN PATIENTS AFFECTED WITH RHEUMATOID ARTHRITIS (RA), SPONDYLOARTHRITIS (SPA), AND PSORIATIC ARTHRITIS (PSA) IN REAL-WORLD SETTINGS
Di Carlo, M;Salaffi, F;
2017-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
